Humira is the world's best-selling drug, bringing in $9.6 billion last year. The way drug information specialist EvaluatePharma sees it, AbbVie's ($ABBV) gem is going to remain the...
A 9-year run for VLST has ended. The Seattle biotech outfit has peddled assets to undisclosed buyers for undisclosed terms and shut its doors for good, Xconomy 's Luke Timmerman reported.
Novartis says that one of its top Phase III drug prospects beat out Enbrel in a head-to-head showdown on psoriasis. Investigators say that the anti-IL17A secukinumab (AIN457) nabbed all the primary and secondary endpoints in the study.
Amgen was delivered a nasty surprise about its superblockbuster Enbrel this week when a new study found that a cocktail of generics already on the market was as effective at treating rheumatoid arthritis.
Pfizer has big expectations for its oral rheumatoid arthritis treatment Xeljanz--about $3 billion worth. But those expectations were struck a serious blow when European Medicines Agency regulators Thursday turned it down for approval.
While the FDA continues its slow-motion release of new guidelines for producing biosimilars in the U.S., India's Cipla has stepped up with a knockoff of the rheumatoid arthritis blockbuster Enbrel, which it will sell in the subcontinent at a 30% discount.
Just two months after Merck dropped out of a snake-bit biosimilar development program for Enbrel, the pharma giant--which has experienced a number of setbacks in the field--has stepped back up with a new, high-profile partnership, teaming up with a new venture formed by the South Korean conglomerate Samsung and Biogen Idec.
In Hollywood, when undercover agents are planning to secretly record a meeting, there's often a scene meant to engage the audience's fear and sympathy: "Are you wearing a wire?" someone accuses, usually someone armed with a gun or enormous fists.
Amgen's long-brewing settlement with the U.S. Justice Department is close at hand. The drugmaker pleaded guilty today to a misdemeanor misbranding charge for mismarketing its anemia drug Aranesp.
Some of the biggest blockbusters known to the pharma industry have dropped off the patent cliff and tumbled into the brutal land of generic therapies, where low-priced competition lays sales to...